Oral submucous fibrosis

From WikiMD's Food, Medicine & Wellness Encyclopedia

Oral submucous fibrosis (OSF) is a chronic, complex, premalignant condition of the oral cavity and the oropharynx, characterized by juxta-epithelial inflammatory reaction and progressive fibrosis of the submucosal tissues. It results in marked rigidity and an eventual inability to open the mouth. The condition is linked to oral cancers and is associated predominantly with the chewing of areca nut.

Etiology[edit | edit source]

The etiology of OSF is multifactorial. The main causative factor is the chewing of areca nut, a habit common in the Indian subcontinent and Southeast Asia. Other factors include nutritional deficiencies, immunologic processes, and genetic predisposition.

Pathogenesis[edit | edit source]

The pathogenesis of OSF is a complex process of changes in the oral mucosa. The chewing of areca nut causes a higher release of fibrogenic cytokines from the oral mucosa. This leads to increased collagen deposition and decreased collagen degradation, resulting in fibrosis.

Clinical features[edit | edit source]

OSF presents with recurrent ulceration, pain in the oral cavity, burning sensation, and difficulty in eating and opening the mouth. In advanced stages, there may be difficulty in speech, hearing, and swallowing.

Diagnosis[edit | edit source]

Diagnosis of OSF is based on clinical examination, history taking, and biopsy. The histopathological examination shows epithelial atrophy, chronic inflammation, and fibrosis.

Treatment[edit | edit source]

Treatment of OSF includes cessation of areca nut chewing, pharmacotherapy, physiotherapy, and surgical intervention. However, the prognosis is poor due to the high risk of malignant transformation.

See also[edit | edit source]

Oral submucous fibrosis Resources
Doctor showing form.jpg
Wiki.png

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD


Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.

Contributors: Prab R. Tumpati, MD